Ketoconazole exacerbates mitophagy to induce apoptosis by downregulating cyclooxygenase-2 in hepatocellular carcinoma.

[1]  A. Thorburn,et al.  Targeting autophagy in cancer , 2017, Nature Reviews Cancer.

[2]  Lei Chen,et al.  New knowledge of the mechanisms of sorafenib resistance in liver cancer , 2017, Acta Pharmacologica Sinica.

[3]  L. Schöckel,et al.  Mitochondrial complex I inhibition triggers a mitophagy-dependent ROS increase leading to necroptosis and ferroptosis in melanoma cells , 2017, Cell Death and Disease.

[4]  M. Andreeff,et al.  Targeting FLT3-ITD signaling mediates ceramide-dependent mitophagy and attenuates drug resistance in AML. , 2016, Blood.

[5]  R. Ordoñez,et al.  Melatonin‐induced increase in sensitivity of human hepatocellular carcinoma cells to sorafenib is associated with reactive oxygen species production and mitophagy , 2016, Journal of pineal research.

[6]  E. White,et al.  Recent insights into the function of autophagy in cancer , 2016, Genes & development.

[7]  S. Chakrapani,et al.  VCP recruitment to mitochondria causes mitophagy impairment and neurodegeneration in models of Huntington's disease , 2016, Nature Communications.

[8]  J. Bruix,et al.  Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma. , 2016, Gastroenterology.

[9]  Akinori Eiyama,et al.  PINK1/Parkin-mediated mitophagy in mammalian cells. , 2015, Current opinion in cell biology.

[10]  C. Mathers,et al.  Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.

[11]  G. Washko,et al.  Mitophagy-dependent necroptosis contributes to the pathogenesis of COPD. , 2014, Journal of Clinical Investigation.

[12]  J. Lemasters.  Variants of mitochondrial autophagy: Types 1 and 2 mitophagy and micromitophagy (Type 3)☆ , 2014, Redox biology.

[13]  S. Fox,et al.  COX-2 expression is predictive for early relapse and aromatase inhibitor resistance in patients with ductal carcinoma in situ of the breast, and is a target for treatment , 2014, British Journal of Cancer.

[14]  D. Green,et al.  To Be or Not to Be? How Selective Autophagy and Cell Death Govern Cell Fate , 2014, Cell.

[15]  G. Gores,et al.  Hepatocellular carcinoma: clinical frontiers and perspectives , 2014, Gut.

[16]  Shanshan Wang,et al.  Phosphorylated AKT inhibits the apoptosis induced by DRAM-mediated mitophagy in hepatocellular carcinoma by preventing the translocation of DRAM to mitochondria , 2014, Cell Death and Disease.

[17]  Hongchuan Jin,et al.  Regulation and function of mitophagy in development and cancer , 2013, Autophagy.

[18]  Yan-wen Zhang,et al.  Dynamin 1-like-dependent mitochondrial fission initiates overactive mitophagy in the hepatotoxicity of cadmium , 2013, Autophagy.

[19]  P. Boya,et al.  Emerging regulation and functions of autophagy , 2013, Nature Cell Biology.

[20]  J. Hynes,et al.  A high-throughput dual parameter assay for assessing drug-induced mitochondrial dysfunction provides additional predictivity over two established mitochondrial toxicity assays. , 2013, Toxicology in vitro : an international journal published in association with BIBRA.

[21]  Y. Peterson,et al.  Ceramide targets autophagosomes to mitochondria and induces lethal mitophagy , 2012, Nature chemical biology.

[22]  A. M. van der Bliek,et al.  Mitochondrial Fission, Fusion, and Stress , 2012, Science.

[23]  B. Honig,et al.  Structure-based prediction of protein-protein interactions on a genome-wide scale , 2012, Nature.

[24]  T. Schwarz,et al.  The pathways of mitophagy for quality control and clearance of mitochondria , 2012, Cell Death and Differentiation.

[25]  D. Klionsky,et al.  Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) , 2012, Autophagy.

[26]  Joon-Kee Yoon,et al.  Involvement of mitophagy in oncogenic K-Ras-induced transformation , 2011, Autophagy.

[27]  M. Rizzo.  Cyclooxygenase-2 in oncogenesis. , 2011, Clinica chimica acta; international journal of clinical chemistry.

[28]  B. Goh,et al.  Pharmacokinetics and pharmacodynamics of docetaxel with or without ketoconazole modulation in chemonaive breast cancer patients. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[29]  Lewis R. Roberts,et al.  Hepatocellular carcinoma: a global view , 2010, Nature Reviews Gastroenterology &Hepatology.

[30]  P. Kantoff,et al.  Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  Dieter Häussinger,et al.  Sorafenib in advanced hepatocellular carcinoma. , 2008, The New England journal of medicine.

[32]  C. Trautwein,et al.  Cyclooxygenase-2 inhibition induces apoptosis signaling via death receptors and mitochondria in hepatocellular carcinoma. , 2006, Cancer research.

[33]  S. Shyue,et al.  Mitochondrial localization of cyclooxygenase-2 and calcium-independent phospholipase A2 in human cancer cells: implication in apoptosis resistance. , 2005, Experimental cell research.

[34]  Daniel J Klionsky,et al.  Development by self-digestion: molecular mechanisms and biological functions of autophagy. , 2004, Developmental cell.

[35]  E. Small,et al.  Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  J. Sobel,et al.  Guidelines for treatment of candidiasis. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[37]  K. Subbaramaiah,et al.  Targeting cyclooxygenase-2 in human neoplasia: rationale and promise. , 2003, Cancer cell.

[38]  K. Subbaramaiah,et al.  Cyclooxygenase 2: a molecular target for cancer prevention and treatment. , 2003, Trends in pharmacological sciences.

[39]  P. Schirmacher,et al.  Proapoptotic and antiproliferative potential of selective cyclooxygenase‐2 inhibitors in human liver tumor cells , 2002, Hepatology.

[40]  E. García-Martín,et al.  Expression of paclitaxel-inactivating CYP3A activity in human colorectal cancer: implications for drug therapy , 2002, British Journal of Cancer.

[41]  Shinichi Watanabe,et al.  Ketoconazole suppresses prostaglandin E(2)-induced cyclooxygenase-2 expression in human epidermoid carcinoma A-431 cells. , 2002, The Journal of investigative dermatology.

[42]  S. Bae,et al.  Expression of cyclooxygenase-2 (COX-2) in hepatocellular carcinoma and growth inhibition of hepatoma cell lines by a COX-2 inhibitor, NS-398. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[43]  William L. Smith,et al.  Prostaglandin Endoperoxide H Synthases (Cyclooxygenases)-1 and −2* , 1996, The Journal of Biological Chemistry.

[44]  J. Trachtenberg,et al.  KETOCONAZOLE THERAPY FOR ADVANCED PROSTATE CANCER , 1984, The Lancet.

[45]  J. Heeres,et al.  Antimycotic imidazoles. part 4. Synthesis and antifungal activity of ketoconazole, a new potent orally active broad-spectrum antifungal agent. , 1979, Journal of medicinal chemistry.

[46]  R. Youle,et al.  Mechanisms of mitophagy , 2010, Nature Reviews Molecular Cell Biology.

[47]  D. Acosta,et al.  Inhibition of mitochondrial function in isolated rate liver mitochondria by azole antifungals. , 1996, Journal of biochemical toxicology.